Investigational Drug Information for BLU-5937
✉ Email this page to a colleague
What is the development status for investigational drug BLU-5937?
BLU-5937 is an investigational drug.
There have been 9 clinical trials for BLU-5937.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2022.
The most common disease conditions in clinical trials are Cough, Pruritus, and Eczema. The leading clinical trial sponsors are Bellus Health Inc and [disabled in preview].
There are four US patents protecting this investigational drug and fifty-two international patents.
Summary for BLU-5937
US Patents | 4 |
International Patents | 52 |
US Patent Applications | 33 |
WIPO Patent Applications | 4 |
Japanese Patent Applications | 0 |
Clinical Trial Progress | Phase 1 (2022-10-01) |
Vendors | 7 |
Recent Clinical Trials for BLU-5937
Title | Sponsor | Phase |
---|---|---|
Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant | Bellus Health Inc | Phase 1 |
Assessment of the Pharmacokinetics of BLU-5937 Extended Release Formulation | Bellus Health Inc | Phase 1 |
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough | Bellus Health Inc | Phase 3 |
Clinical Trial Summary for BLU-5937
Top disease conditions for BLU-5937
Top clinical trial sponsors for BLU-5937
US Patents for BLU-5937
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
BLU-5937 | ⤷ Try a Trial | Selective P2X3 modulators | BELLUS HEALTH COUGH INC. (Laval, Quebec, CA) NEOMED INSTITUTE (Montreal, Quebec, CA) | ⤷ Try a Trial |
BLU-5937 | ⤷ Try a Trial | Imidazopyridine compounds and uses thereof | Neomed Institute (Montreal, Quebec, CA) | ⤷ Try a Trial |
BLU-5937 | ⤷ Try a Trial | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents | NeRRe Therapeutics Limited (Herts, GB) | ⤷ Try a Trial |
BLU-5937 | ⤷ Try a Trial | Imidazopyridine compounds and uses thereof | ⤷ Try a Trial | |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BLU-5937
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
BLU-5937 | Australia | AU2018342751 | 2037-09-18 | ⤷ Try a Trial |
BLU-5937 | Canada | CA3076150 | 2037-09-18 | ⤷ Try a Trial |
BLU-5937 | China | CN111601601 | 2037-09-18 | ⤷ Try a Trial |
BLU-5937 | European Patent Office | EP3684368 | 2037-09-18 | ⤷ Try a Trial |
BLU-5937 | Israel | IL273348 | 2037-09-18 | ⤷ Try a Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |